Cargando…
Transcatheter arterial chemoembolization with spherical embolic material for locally advanced breast cancer: first report of HepaSphere™ treatment for primary breast cancer
A 57-year-old female was diagnosed as having primary breast cancer (invasive carcinoma of no special type), which was immunohistochemically negative for oestrogen receptor, androgen receptor and human epidermal growth factor receptor Type 2. The main tumour was 54 × 35 mm in size and was located in...
Autores principales: | Kennoki, Norifumi, Hori, Shinichi, Hori, Atsushi, Takeo, Yuki, Oshiro, Hisashi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The British Institute of Radiology
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6243306/ https://www.ncbi.nlm.nih.gov/pubmed/30460025 http://dx.doi.org/10.1259/bjrcr.20150417 |
Ejemplares similares
-
Long-term Histopathologic Follow-up of a Spherical Embolic Agent; Observation of the Transvascular Migration of HepaSphere(TM)
por: Kennoki, Norifumi, et al.
Publicado: (2019) -
Effects of HepaSphere microsphere encapsule epirubicin with a new loading method transarterial chemoembolization: in vitro and in vivo experiments
por: Zhang, Wen, et al.
Publicado: (2023) -
Assessment of efficacy and safety by CalliSpheres versus HepaSpheres for drug-eluting bead transarterial chemoembolization in unresectable large hepatocellular carcinoma patients
por: Zhao, Guangsheng, et al.
Publicado: (2021) -
Initial Transarterial Chemoembolization (TACE) Using HepaSpheres 20–40 µm and Subsequent Lipiodol TACE in Patients with Hepatocellular Carcinoma > 5 cm
por: Cho, Su Min, et al.
Publicado: (2021) -
Hepatic fibrosis and short-term clinical efficacy after hepatic artery embolization for unresectable hepatocellular carcinoma using doxorubicin-eluting HepaSphere
por: Chen, Meng, et al.
Publicado: (2020)